Sean Mackay, IsoPlexis
January 8, 2021 10:44 AM ESTUpdated July 26, 02:25 PM
Financing

Iso­Plex­is scores big backer for per­son­al­ized pro­tein 'bar­codes' as Per­cep­tive jumps on board new fund­ing round

Max Gelman

Senior Editor

A lit­tle less than two years af­ter bag­ging an ex­tend­ed $50 mil­lion Se­ries C, Iso­Plex­is and its “pro­teom­ic bar­codes” for per­son­al­ized can­cer care are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times